

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Michael Polydefkis¹, Emre Aldinc², Hans Nienhuis³, Chafic Karam⁴, Senda Ajroud-Driss⁵, Yoshiki Sekijima⁶, Marcia Waddington-Cruz⁷, Jennifer Barnes², Paul Nioi², Simina Ticau²

¹Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Alnylam Pharmaceuticals, Cambridge, MA, USA; ³Amyloidosis Centre of Expertise, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; ⁴Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; ⁵Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ⁶Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan; ⁷CEPARM, National Amyloidosis Referral Center, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Poster originally presented at the Annual Meeting of the American Neurological Association (ANA) 2022, October 23, 2022
April 22–27, 2023 || 75th Annual Meeting of the American Academy of Neurology (AAN) 2023



Author Disclosures for Dr. Michael Polydefkis

Conflict	Disclosures
Akcea, Alnylam Pharmaceuticals, Pfizer	Participation in clinical trials
Akcea, Alnylam Pharmaceuticals, Biogen-Idec, Pfizer, Vertex Pharmaceuticals	Consultancy fees

- This study was funded by Alnylam Pharmaceuticals. Medical writing assistance was provided by Christopher Bulman, PhD, of Adelphi Communications Ltd, UK, and funded by Alnylam Pharmaceuticals in accordance with Good Publication Practice Guidelines

Background and Rationale

hATTR Amyloidosis

- A rare, underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by variants in the *TTR* gene^{1–5}
- Diagnosis is difficult and often delayed,^{6,7} and monitoring disease progression and treatment response can be challenging^{8–13}

Neurofilament Light Chain (NfL)

- An abundant, highly conserved, neuron-specific, structural neurofilament protein¹⁴
- Elevated plasma NfL levels are seen in various diseases presenting with neuropathy,^{15–22} presumed to result from NfL release following neuroaxonal injury, making NfL a biomarker for nerve damage^{23,24}
- Reliable quantitative measurements of blood NfL levels are now possible in the clinic
- NfL has been proposed as a potential biomarker of disease progression and treatment response in patients with hATTR amyloidosis with polyneuropathy^{25,26}


hATTR, hereditary transthyretin-mediated; NfL, neurofilament light chain; TTR, transthyretin.

1. Hanna et al. *Curr Heart Fail Rep* 2014;11:50–7; 2. Mohty et al. *Arch Cardiovasc Dis* 2013;106:528–40; 3. Adams et al. *Neurology* 2015;85:675–82; 4. Damy et al. *J Cardiovasc Transl Res* 2015;8:117–27; 5. Hawkins et al. *Ann Med* 2015;47:625–38; 6. Adams et al. *Curr Opin Neurol* 2016;29(Suppl. 1):S14–26; 7. Obici et al. *Curr Opin Neurol* 2016;29(Suppl. 1):S27–35; 8. Adams et al. *Curr Opin Neurol* 2012;25:564–72; 9. Adams et al. *Amyloid* 2012;19(Suppl. 1):61–4; 10. Plante-Bordeneuve et al. *Neurology* 2007;69:693–8; 11. Plante-Bordeneuve et al. *J Med Genet* 2003;40:e120; 12. Mazzeo et al. *J Neuromuscul Dis* 2015;2:S39–48; 13. Alves-Ferreira et al. *Mol Neurobiol* 2018;55:3676–83; 14. Fuchs & Cleveland *Science* 1998;279:514–9; 15. Gunnarsson et al. *Ann Neurol* 2011;69:83–9; 16. Lewczuk et al. *Alzheimers Res Ther* 2018;10:71; 17. Lin et al. *Sci Rep* 2018;8:17368; 18. Byrne et al. *Lancet Neurol* 2017;16:601–9; 19. Bischof et al. *Ann Rheum Dis* 2018;77:1093–4; 20. van Lieverloo et al. *J Peripher Nerv Syst* 2019;24:187–94; 21. Mariotto et al. *J Peripher Nerv Syst* 2018;23:174–7; 22. Sandelius et al. *Neurology* 2018;90:e518–24; 23. Lycke et al. *J Neurol Neurosurg Psychiatry* 1998;64:402–4; 24. Preische et al. *Nat Med* 2019;25:277–83; 25. Louwsma et al. *Amyloid* 2021;28:50–5; 26. Tica et al. *Neurology* 2021;96:e412–22.

Objective

To characterize the effect of the RNAi therapeutics, vutrisiran and patisiran, on NfL levels in hATTR amyloidosis with polyneuropathy and further assess the potential utility of NfL to monitor disease progression and treatment response

Therapeutic Hypothesis




Methods

- Patients enrolled in the APOLLO¹ or HELIOS-A² studies were included in this post hoc analysis if they had sufficient plasma sample for biomarker investigation and consented to the use of their sample
- Samples were also collected in healthy controls who were age- and sex-matched to the APOLLO population
- NfL plasma levels were measured in healthy controls and in patients with hATTR amyloidosis with polyneuropathy using the Quanterix[®] Simoa[™] platform
- Quantitative NfL analyses were conducted at the time points below:
 - **APOLLO study (double-blind):** baseline^a, 21 days, 4 months, and 18 months in placebo and patisiran groups
 - **HELIOS-A study (open-label):** baseline, 43 days, 4 months, 9 months, and 18 months in vutrisiran and patisiran groups



Treatment Arms of the APOLLO and HELIOS-A Studies



^aBaseline, first dose of patisiran. hATTR, hereditary transthyretin-mediated; IV, intravenous; mNIS+7, modified Neuropathy Impairment Score +7; NfL, neurofilament light chain; Q3M, every 3 months; Q3W, every 3 weeks; SC, subcutaneous.
 1. Adams D et al. *N Engl J Med* 2018;379:11–21. 2. Adams D et al. *Amyloid*. 2023 Mar;30:18-26.


Baseline Characteristics of Patients with NfL Assessments

- Overall, the baseline demographics and characteristics for HELIOS-A and APOLLO patient populations were widely overlapping and clinically comparable

Characteristic	APOLLO		HELIOS-A	
	Placebo (n=47)	Patisiran (n=111)	Vutrisiran (n=111)	Patisiran (n=36)
Age, median (range), years	64 (34–80)	63 (27–83)	60 (31–81)	61 (31–81)
Male, n (%)	36 (77)	85 (77)	69 (62)	23 (64)
TTR genotype, n (%)				
V30M	24 (51)	47 (42)	48 (43)	16 (44)
Non-V30M	23 (49)	64 (58)	63 (57)	20 (56)
Prior TTR stabilizer use, n (%)	25 (53)	65 (59)	66 (59)	29 (81)
NIS, mean (range)	55.9 (7–119)	60.5 (6–142)	42.4 (5–127)	44 (5.5–115.6)
mNIS+7, mean (range)	74.1 (17–151)	80.9 (8–163)	60.1 (2.5–158)	60.9 (7–137.6)
PND score, n (%)				
I: preserved walking, sensory disturbances	11 (23)	24 (22)	42 (38)	14 (39)
II: impaired walking but can walk without stick or crutch	17 (36)	32 (29)	44 (40)	14 (39)
IIIA: walk with 1 stick or crutch	13 (28)	33 (30)	13 (12)	5 (14)
IIIB: walk with 2 sticks or crutches	6 (13)	22 (20)	12 (11)	3 (8)

Baseline NfL Levels of Patients in APOLLO and HELIOS-A


- Mean NfL levels in the total patient population at baseline were slightly higher in APOLLO (**69.4 pg/mL**) than in HELIOS-A (**58.2 pg/mL**), but did not differ significantly between treatment groups within each study
- Baseline NfL levels in the patient populations of both studies were significantly higher than in healthy controls (p-value <0.001)



Association between Baseline mNIS+7 and NfL Levels in HELIOS-A

- In HELIOS-A, a moderate correlation ($R=0.49$) was observed between mNIS+7 and NfL levels of vutrisiran- and patisiran-treated patients at baseline
 - The strongest correlation was observed with the nerve conduction studies subcomponent of mNIS+7 ($R=0.59$); other subcomponents showed mild-to-moderate correlations with NfL levels (data on file)


Correlation between Baseline mNIS+7 and NfL Levels in HELIOS-A



NfL Levels Decreased Significantly with TTR RNAi Therapeutics Compared with Placebo

- In APOLLO, NfL levels increased significantly from baseline in the placebo group as early as 4 months ($p < 0.001$), and decreased significantly from baseline in the patisiran group at the same time point ($p < 0.001$)
- Similarly in HELIOS-A, NfL levels in both the vutrisiran and patisiran groups decreased significantly from baseline by 4 months ($p < 0.05$), and these significant reductions were maintained at 18 months ($p < 0.01$)


Change in NfL Levels from Baseline in APOLLO and HELIOS-A Studies



Association between Change in mNIS+7 and Change in NfL Levels in APOLLO and HELIOS-A

- A positive moderate correlation ($R=0.32$) was observed between change in NfL levels and change in mNIS+7 in HELIOS-A and APOLLO at 18 months

Correlation between Change in mNIS+7 and Change in NfL Levels from Baseline in APOLLO and HELIOS-A



Summary

- In the HELIOS-A study, NfL levels significantly decreased as early as 4 months following initiation of the RNAi therapeutics vutrisiran or patisiran, and these reductions from baseline were maintained through 18 months of treatment
 - The observed decreases in NfL levels following treatment in HELIOS-A were consistent with the results in patisiran-treated patients from APOLLO
 - In contrast, NfL levels significantly increased in placebo-treated patients from APOLLO as early as 4 months and continued to increase over 18 months
- Baseline NfL levels were positively correlated with baseline mNIS+7 scores in HELIOS-A, suggestive of NfL being an indicator of disease severity
- Changes from baseline in NfL levels and mNIS+7 at 18 months were also positively correlated across HELIOS-A and APOLLO, which suggest that the degree of reduction of NfL may be associated with the level of improvement in polyneuropathy
- These results collectively support the utility of NfL as a biomarker of disease severity, disease progression, and treatment response over time, and provide biological evidence that reinforces the demonstrated clinical efficacy of patisiran and vutrisiran in patients with hATTR amyloidosis with polyneuropathy

| | Thank you to the patients, their families, investigators, study staff, and collaborators for their participation in the HELIOS-A study, especially considering the challenges of continuing the study during the COVID-19 pandemic